News
Dr. Juliane Fischer joins Dynamic42 as Marketing Manager
We are delighted to announce that Dr. Juliane Fischer has joined our team and will from now on heading all Marketing efforts at Dynamic42.
Read MoreDynamic42 was founded in the spring of 2018 in the high-tech city of Jena and is currently located at the BioInstrumentezentrum on the Beutenberg. The still young company is a spin-off of the University Hospital Jena. We develop and market novel, three-dimensional, human organ models (so-called organ-on-chip technology) for preclinical research and development as well as for testing novel pharmaceutical products, chemicals and food additives.
We are specialized in the area of organ-on-chip technology in the integration of the immune system, which plays a significant role in the occurence of adverse effects of drugs and has been neglected in the industry and in two-dimensional test systems. Our platform enables toxicity screenings and ADMET studies already in preclinical phases on complex microphysiological models of human organs. Hereby we accompany commercial manufacturers as well as scientists in the field of research and development in the design and execution of preclinical studies.
In addition, we develop human disease models in our chip platform both internally and with external partners – especially in areas where no animal models are available.
With the provision of human microphysiological systems / organ-on-chip technology, Dynamic42 GmbH addresses critical points in the development of applications for many areas where chemical substances and biological compounds come into direct contact with humans or are used in products for humans. Here, we contribute to increase the validity of data obtained during pre-clinical trial phases by testing on human microphysiological organ models. Thus, results are better transferable into the human situation in clinical trial phases.
To achieve this, we offer a major advantage with many years of expertise in handling and integrating immune cells into our human microphysiological models as tissue-resident components or via the circulation within the cell culture media.
On the one hand, testing in our human microphysiological models will improve the development of compounds with less side effects for humans. On the other hand, chances of costly adjustments or even termination of studies in late-stage clinical trial phases will be reduced.
Concomitant, we strive to reduce animal experimentation by using our microphysiological systems. Due to their cellular complexity, they offer increased data validity compared to standard cell culture of individual cell types. Subsequently, animal experimentation can thus be kept at a minimal level. Further, if the development of a standard alternative test method is considered for individual applications, we would like to contribute to establish and provide solutions in those cases.
Our company would like to contribute to the economical and sustainable development of pharmaceuticals and additives. We want to distribute modern, human cell culture-based solutions with integrated latest technologies in order to minimize or replace animal experimentation. Thus, our principle is to promote ethical values and sustainability in research and development.
Secondly, the well-being of humans represents an important value to our companies identity. The improvement of developmental procedures and test methods by using complex human microphysiological organ models enables an increase in safety of newly developed drugs and additives and decreases their chance in bearing severe side effects. Our daily motivation is to develop new applications as well as to improve and technologically expand our platform to achieve these goals.
We are looking for you! Whether as a researcher or administrative employee – there is still room for you in our team. Take a look at our vacancies now. Didn’t find a suitable position? Then simply apply on your own initiative!
We are delighted to announce that Dr. Juliane Fischer has joined our team and will from now on heading all Marketing efforts at Dynamic42.
Read MoreFollowing their Master's studies, Daria and Sophie join our lab team as research assistants.
Read MoreThe RUBIN Alliance "ATHANA" (antifungal therapy approaches with nanoparticle-based targeting of drugs) is developing innovative therapeutic approaches for the treatment of infectious diseases, in particular fungal infections.
Read More
Sign up now for our Dynamic42 newsletter and don’t miss anything else from the orang-on-a-chip industry!